shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. compounds derived from shattuck’s proprietary agonist redirected checkpoint, arc®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. the company’s lead wholly owned program, sl-172154 (sirpα-fc-cd40l), which is designed to block the cd47 immune checkpoint and simultaneously agonize the cd40 pathway, is being evaluated in a phase 1 trial. a second compound, sl-279252 (pd1-fc-ox40l), is being evaluated in a phase 1 trial in collaboration with takeda pharmaceuticals. additionally, the company is advancing a proprietary gamma delta t cell engager, gadlen™, platform, which is designed to bridge gamma delta t cells to tumor antigens for the treatment of patients with cancer. shattuck has offices in both austin, tex
Company profile
Ticker
STTK
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
812575858
STTK stock data
Latest filings (excl ownership)
8-K
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
4 Mar 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
29 Feb 24
8-K
Entry into a Material Definitive Agreement
13 Feb 24
424B3
Prospectus supplement
2 Feb 24
EFFECT
Notice of effectiveness
1 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
UPLOAD
Letter from SEC
30 Jan 24
S-3
Shelf registration
24 Jan 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 40.63 mm | 40.63 mm | 40.63 mm | 40.63 mm | 40.63 mm | 40.63 mm |
Cash burn (monthly) | 10.42 mm | (no burn) | 9.53 mm | 8.27 mm | 5.58 mm | 7.14 mm |
Cash used (since last report) | 69.67 mm | n/a | 63.73 mm | 55.32 mm | 37.29 mm | 47.72 mm |
Cash remaining | -29.04 mm | n/a | -23.10 mm | -14.68 mm | 3.34 mm | -7.09 mm |
Runway (months of cash) | -2.8 | n/a | -2.4 | -1.8 | 0.6 | -1.0 |
Institutional ownership, Q3 2023
46.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 42 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 6 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 29.83 bn |
Total shares | 21.98 mm |
Total puts | 500.00 |
Total calls | 700.00 |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
FMR | 6.33 mm | $9.63 bn |
Redmile | 5.62 mm | $8.54 bn |
Prosight Management | 2.12 mm | $3.23 bn |
TAK Takeda Pharmaceutical | 2.09 mm | $17.79 mm |
Clark Estates | 1.48 mm | $2.24 bn |
Vanguard | 1.17 mm | $1.78 bn |
Laurion Capital Management | 506.00 k | $769.12 mm |
BLK Blackrock | 494.12 k | $751.07 mm |
Pinnacle Associates | 487.45 k | $740.92 mm |
Geode Capital Management | 342.94 k | $521.41 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Redmile | Common Stock | Other | Dispose J | Yes | No | 0 | 4,425 | 0.00 | 5,615,489 |
6 Mar 24 | Amy Kate Sasser | Stock Option Common Stock | Grant | Acquire A | No | No | 9.47 | 33,409 | 316.38 k | 33,409 |
6 Mar 24 | Siegall Clay B | Stock Option Common Stock | Grant | Acquire A | No | No | 9.47 | 33,409 | 316.38 k | 33,409 |
6 Mar 24 | Stephen Stout | Common Stock | Sell | Dispose S | No | Yes | 10.53 | 4,895 | 51.54 k | 74,437 |
6 Mar 24 | Stephen Stout | Common Stock | Sell | Dispose S | No | Yes | 10.53 | 6,459 | 68.01 k | 79,332 |
6 Mar 24 | Stephen Stout | Common Stock | Option exercise | Acquire M | No | No | 3.57 | 6,459 | 23.06 k | 85,791 |
6 Mar 24 | Stephen Stout | Common Stock | Sell | Dispose S | No | Yes | 10.53 | 4,650 | 48.96 k | 79,332 |
6 Mar 24 | Stephen Stout | Common Stock | Option exercise | Acquire M | No | No | 3.51 | 4,650 | 16.32 k | 83,982 |
6 Mar 24 | Stephen Stout | Stock Option Common Stock | Option exercise | Dispose M | No | No | 3.57 | 6,459 | 23.06 k | 17,391 |
6 Mar 24 | Stephen Stout | Stock Option Common Stock | Option exercise | Dispose M | No | No | 3.51 | 4,650 | 16.32 k | 9,300 |
News
Shattuck Labs Reports Preclinical Data Demonstrating Therapeutic Utility Of TRIM7 Inhibition To Prevent Or Reverse Acquired Resistance To Immune Checkpoint Therapy
9 Apr 24
Needham Reiterates Buy on Shattuck Labs, Maintains $12 Price Target
9 Apr 24
Needham Reiterates Buy on Shattuck Labs, Maintains $12 Price Target
1 Mar 24
HC Wainwright & Co. Reiterates Buy on Shattuck Labs, Maintains $28 Price Target
1 Mar 24
Shattuck Labs Q4 EPS $(0.41) Beats $(0.57) Estimate
29 Feb 24
Press releases
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
9 Apr 24
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
14 Feb 24
Thinking about buying stock in Avinger, Cloudflare, Backblaze, Shattuck Labs, or Beamr Imaging?
13 Feb 24
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
13 Feb 24